Acadian Asset Management LLC Takes Position in Keros Therapeutics, Inc. $KROS

Acadian Asset Management LLC bought a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) during the 1st quarter, according to its most recent filing with the SEC. The fund bought 147,567 shares of the company’s stock, valued at approximately $1,502,000. Acadian Asset Management LLC owned approximately 0.36% of Keros Therapeutics as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Two Sigma Investments LP boosted its position in shares of Keros Therapeutics by 226.1% during the 4th quarter. Two Sigma Investments LP now owns 33,664 shares of the company’s stock valued at $533,000 after acquiring an additional 23,342 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Keros Therapeutics during the 4th quarter valued at about $730,000. Jump Financial LLC acquired a new stake in shares of Keros Therapeutics during the 1st quarter valued at about $1,058,000. Tejara Capital Ltd acquired a new stake in shares of Keros Therapeutics during the 1st quarter valued at about $410,000. Finally, TFG Asset Management GP Ltd acquired a new stake in shares of Keros Therapeutics during the 4th quarter valued at about $1,630,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. HC Wainwright decreased their target price on shares of Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Wedbush restated a “neutral” rating and issued a $15.00 price target on shares of Keros Therapeutics in a research report on Friday, May 30th. Finally, Bank of America lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating and reduced their price target for the company from $32.00 to $18.00 in a research report on Tuesday, June 10th. Seven equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $30.00.

Keros Therapeutics Stock Up 1.6%

NASDAQ:KROS opened at $15.80 on Wednesday. The firm has a market cap of $641.80 million, a PE ratio of 50.97, a price-to-earnings-growth ratio of 2.00 and a beta of 1.06. Keros Therapeutics, Inc. has a 12 month low of $9.12 and a 12 month high of $72.37. The company’s 50-day moving average price is $14.70 and its two-hundred day moving average price is $13.56.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.38. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $3.83 million. Keros Therapeutics had a net margin of 8.06% and a return on equity of 2.96%. The company’s revenue for the quarter was up 49002.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.25) earnings per share. On average, research analysts expect that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.